A Phase 2 Study of Jaktinib in Participants With Moderate to Severe Psoriasis

PHASE2CompletedINTERVENTIONAL

Enrollment

123

Participants

Timeline

Start Date

March 11, 2021

Primary Completion Date

August 15, 2022

Study Completion Date

August 15, 2022

Conditions

Moderate-to-Severe Plaque Psoriasis

Interventions

DRUG

Jaktinib

Administered orally

DRUG

Placebo

Administered orally

Trial Locations (1)

The First Affiliated Hospital of China Medical University, Shenyang

All Listed Sponsors

lead

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

INDUSTRY

NCT04612699 - A Phase 2 Study of Jaktinib in Participants With Moderate to Severe Psoriasis | Biotech Hunter | Biotech Hunter